293 related articles for article (PubMed ID: 35586474)
21. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA.
Wu Z; Li X; Zeng Y; Zhuang X; Shen H; Zhu H; Liu H; Xiao H
Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):177-84. PubMed ID: 21073659
[TBL] [Abstract][Full Text] [Related]
23. Molecular therapy using siRNA: Recent trends and advances of multi target inhibition of cancer growth.
Jain S; Pathak K; Vaidya A
Int J Biol Macromol; 2018 Sep; 116():880-892. PubMed ID: 29782974
[TBL] [Abstract][Full Text] [Related]
24. Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer.
She T; Shi Q; Li Z; Feng Y; Yang H; Tao Z; Li H; Chen J; Wang S; Liang Y; Cheng J; Lu X
Theranostics; 2021; 11(9):4281-4297. PubMed ID: 33754061
[TBL] [Abstract][Full Text] [Related]
25. β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.
Bar-Zeev M; Assaraf YG; Livney YD
Oncotarget; 2016 Apr; 7(17):23322-34. PubMed ID: 26989076
[TBL] [Abstract][Full Text] [Related]
26. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
27. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
28. Delivery of small interfering RNAs by nanovesicles for cancer therapy.
Pengnam S; Plianwong S; Yingyongnarongkul BE; Patrojanasophon P; Opanasopit P
Drug Metab Pharmacokinet; 2022 Feb; 42():100425. PubMed ID: 34954489
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors.
Yang X; Wang Y; Chen S; Zhang S; Cui C
Int J Nanomedicine; 2021; 16():7051-7069. PubMed ID: 34703227
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic nanosystems co-deliver anticancer drugs and oncogene SiRNA to achieve synergetic precise cancer chemo-gene therapy.
Huang W; Liang Y; Sang C; Mei C; Li X; Chen T
J Mater Chem B; 2018 May; 6(19):3013-3022. PubMed ID: 32254336
[TBL] [Abstract][Full Text] [Related]
31. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
Zhang C; Zhao Y; Zhang E; Jiang M; Zhi D; Chen H; Cui S; Zhen Y; Cui J; Zhang S
Drug Deliv; 2020 Dec; 27(1):1397-1411. PubMed ID: 33096948
[TBL] [Abstract][Full Text] [Related]
32. Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association.
Lee E; Oh C; Kim IS; Kwon IC; Kim S
J Control Release; 2015 Jul; 210():105-14. PubMed ID: 25979325
[TBL] [Abstract][Full Text] [Related]
33. Binary-copolymer system base on low-density lipoprotein-coupled N-succinyl chitosan lipoic acid micelles for co-delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug.
Yang SD; Zhu WJ; Zhu QL; Chen WL; Ren ZX; Li F; Yuan ZQ; Li JZ; Liu Y; Zhou XF; Liu C; Zhang XN
J Biomed Mater Res B Appl Biomater; 2017 Jul; 105(5):1114-1125. PubMed ID: 27008163
[TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
[TBL] [Abstract][Full Text] [Related]
35. Co-delivery of chemotherapeutics and proteins for synergistic therapy.
He C; Tang Z; Tian H; Chen X
Adv Drug Deliv Rev; 2016 Mar; 98():64-76. PubMed ID: 26546464
[TBL] [Abstract][Full Text] [Related]
36. Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics.
Zare M; Pemmada R; Madhavan M; Shailaja A; Ramakrishna S; Kandiyil SP; Donahue JM; Thomas V
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015246
[TBL] [Abstract][Full Text] [Related]
37. Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA.
Suo A; Qian J; Xu M; Xu W; Zhang Y; Yao Y
Mater Sci Eng C Mater Biol Appl; 2017 Jul; 76():659-672. PubMed ID: 28482576
[TBL] [Abstract][Full Text] [Related]
38. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
39. Natural Compounds: Co-Delivery Strategies with Chemotherapeutic Agents or Nucleic Acids Using Lipid-Based Nanocarriers.
Teixeira PV; Fernandes E; Soares TB; Adega F; Lopes CM; Lúcio M
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111802
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
